Using topical non-steroidal anti-inflammatory drugs to relieve the pain of osteoarthritis is only beneficial for the first two weeks

Using topical non-steroidal anti-inflammatory drugs (NSAIDS) to relieve the pain of osteoarthritis is only beneficial for the first two weeks, finds a study available on bmj.com today.

This challenges current guidelines from Europe and America that topical NSAIDS are an effective treatment for osteoarthritis, the most common form of arthritis.

Researchers in Nottingham analysed 13 trials comparing topical NSAIDS with placebo or oral NSAIDS in osteoarthritis. The trials lasted up to four weeks and involved 1,983 patients.

Topical NSAIDS were superior to placebo in relieving pain due to osteoarthritis only in the first two weeks of treatment. Trials lasting four weeks showed no benefit. A similar pattern was found for function and stiffness. Topical NSAIDS were inferior to oral NSAIDS in the first week of treatment and were associated with more local side effects such as rash, itch, or burning.

Evidence to support the long term use (more than one month) of topical NSAIDS in osteoarthritis is absent, say the authors. Current recommendations for their use in osteoarthritis need to be revised, they conclude.

Click here to view full paper: http://press.psprings.co.uk/bmj/july/osteoarthritis.pdf

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding access to GLP-1 weight-loss drugs could save thousands of lives